Korro Bio, Inc. (KRRO) income statement
KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$12.44+0.12 (+0.97%)
Close on Nov 18, 2026Market cap $183.19MP/E –Yield –
Korro Bio, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -4625.5%
- Net margin
- -4477.1%
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 9.55
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 197.2%
Valuation
- P/E ratio
- –
- Price to sales
- 76.90
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?